Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.

LHA-ID
7RWQH17EG8-8
Summary

To study the effects of deferring pegfilgrastim until day 4 on the reduction of chemotherapy-induced leukocytopenia. Patients of age 61-80 years with aggressive lymphoma were randomly assigned to receive 6 mg pegfilgrastim on day 2 or 4 of a 2-week chemotherapy regimen (R-CHOP-14).

Abstract
BACKGROUND: To study the effects of deferring pegfilgrastim until day 4 on the reduction of chemotherapy-induced leukocytopenia. PATIENTS AND METHODS: Patients of age 61-80 years with aggressive lymphoma were randomly assigned to receive 6 mg pegfilgrastim on day 2 or 4 of a 2-week chemotherapy regimen (R-CHOP-14). RESULTS: Two hundred and ninety-two and 313 chemotherapy cycles were evaluable in 103 patients. Post-nadir pegfilgrastim serum levels were higher after day 4 than after day 2 application. This was associated with an attenuated leukocyte nadir after day 4 pegfilgrastim and there were fewer days with leukocytes
DOI
10.1093/annonc/mdq674
Publication Date
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Journal Volume
22
Journal Number
8
Corresponding Author
Prof. Dr. G. Held
Corresponding Author Institution

Studiensekretariat Homburg; Universität des Saarlandes; 66421 Homburg

Corresponding Author email
Publication Type
Human Disease Ontology Concept